Wuxi Biologics Proposes Revised Cap and Renewal of Service Agreement Amid Growing Demand
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Wuxi Biologics (Cayman) ( (HK:2269) ) has provided an update.
Wuxi Biologics announced a proposal to revise the annual cap for its 2023 Payload-Linkers Master Services Agreement due to increased demand and strong performance of the XDC Group. The company plans to renew the agreement for three more years, subject to shareholder approval, to accommodate the continued growth in demand for its ADC CRDMO services, reflecting its strategic positioning in the expanding biopharmaceutical market.
The most recent analyst rating on (HK:2269) stock is a Hold with a HK$36.00 price target. To see the full list of analyst forecasts on Wuxi Biologics (Cayman) stock, see the HK:2269 Stock Forecast page.
More about Wuxi Biologics (Cayman)
Wuxi Biologics (Cayman) Inc. is a company involved in the biopharmaceutical industry, focusing on research, development, and manufacturing services related to payload-linkers, which are used in ADC CRDMO services. The company is positioned in a rapidly expanding industry with growing demand for its services.
Average Trading Volume: 53,885,551
Technical Sentiment Signal: Buy
Current Market Cap: HK$135.1B
Find detailed analytics on 2269 stock on TipRanks’ Stock Analysis page.
